Amplia Therapeutics Secures Ethics Approval for Pancreatic Cancer Drug Trial
Amplia Therapeutics has received approval to begin a new clinical trial for its pancreatic cancer drug, narmafotinib, aiming to secure data for future U.S.

Amplia Therapeutics has received ethics approval to initiate the "ACCENT-Mini" clinical trial, which will evaluate the efficacy and safety of its lead drug candidate, narmafotinib, in combination with chemotherapy for patients with metastatic pancreatic cancer. The trial will commence patient recruitment across three Australian clinical sites to establish an optimal daily-dosing regimen.
This study follows previous clinical data indicating that narmafotinib, a Focal Adhesion Kinase (FAK) inhibitor, achieved a 36% tumor response rate and a median overall survival of 11.1 months when administered with standard chemotherapy. By inhibiting FAK, the drug aims to reduce the fibrotic tissue surrounding solid tumors, potentially increasing the efficacy of existing chemotherapy treatments.
Food and Drug Administration
The company expects to generate safety and pharmacokinetic data from this trial by late Q1 or early Q2 of 2027. These results are intended to support a formal protocol submission to the U.S. Food and Drug Administration (FDA) for a larger, registrational study.
Strategic interest in this trial is heightened by Strategic interest in this trial is heightened by the prevalence of KRAS gene mutations in over 90% of pancreatic cancer cases. As the FDA continues to approve new KRAS-targeting therapies, the potential for narmafotinib to function as a complementary treatment in combination regimens remains a key focus for the company’s clinical development pipeline.
Successful outcomes from the ACCENT-Mini trial are critical for the company’s regulatory strategy. The data will serve as the primary evidence required to design a pivotal study, which is a necessary precursor to seeking commercial approval for the drug in the United States market.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- GSK wins FDA approval for Nelkarmi after 49% response rate
- Europe faces 35,000 drug-resistance deaths a year
- Stomach bug reports widen CDC, FDA food probe in 4 states
- Legionnaires’ disease cases rise to 14 in Manhattan area
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

